Technical Feasibility Evaluation of Mucosal Staining During Colon Capsule Endoscopy (CCE) Procedure in Colorectal Cancer (CRC) High Risk Population, When Using MB-MMX

1. Subject has a previous history or suspicion of inflammatory bowel or Crohn's disease, ulcerative Colitis or indeterminant Colitis

2. Subject has congestive heart failure or recent myocardial infarction (\<3month)

3. Subject with moderate/severe renal disease and/ or severe hepatic impairment

4. Subject has uncontrolled diabetes

5. Subject has a severe, life-threatening disease

6. Subject with known gastrointestinal motility disorders

7. Subject has known delayed gastric emptying

8. Subject has undergone surgery of the luminal gastrointestinal (GI) tract, from esophagus to the rectum, other than uncomplicated appendectomy or cholecystectomy.

9. Subject with any current condition believed to have an increased risk of capsule retention such as suspected or known bowel obstruction or pseudo-obstruction, stricture, or fistula (symptoms such as severe abdominal pain with accompanying nausea or vomiting)

10. Subject with dysphagia, any swallowing disorder, or any major gastrointestinal motility disorder

11. Subject has a history of inadequate bowel preparation for colon imaging with colonoscopy, CTC, CCE, or DCBE (self-reporting)

12. Subject with known or suspected constipation history as defined by the following: as needing the use of medication (prescription or OTC) for management of constipation, or fewer than 3 BM/week regardless of medication use

13. Subject with a cardiac pacemaker or other implanted electromedical device

14. Subject with planned MRI examination within 7 days after ingestion of the capsule

15. The subject is taking antidepressant medicine or a medicine for psychiatric illness, such as:

* selective serotonin reuptake inhibitor (SSRI)- as fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram and zimeldine; bupropion, venlafaxine, mirtazapine, clomipramine, buspirone

* medicines classified as Monamine Oxidase Inhibitors (often used for treating depression).

16. Subject has glucose-6-phosphate dehydrogenase (G6PD) deficiency and/or allergic to peanut/soya

17. Subject consumes any of the medicinal products which interacts with MB-MMX, as per MB-MMX label and Investigator's discretion.

18. Subject with allergies or known contraindication to the device, medications or preparation agents used in the procedure as described in the relevant instructions for use/package inserts.

19. Subject use of opioid medication on a regular basis and requires medication to treat opioid induced constipation

20. Subject currently participating in another gastrointestinal clinical study (investigational drug or device) that might interfere with results of study

21. Females who are pregnant or breastfeeding at time of bowel prep

22. Any condition which precludes compliance with study and/or device instructions based on the clinical judgment of the investigator

23. Subject who is considered to be part of a vulnerable population (e.g. prisoners or those without sufficient mental capacity)

24. Medtronic employees

What this study is about